

Supplemental Information

Montano et al, Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule *in vitro* and *in vivo*

Figure S1. Impact of gemcitabine and MK-8776 on cell cycle perturbation of AsPC-1 cells. Cells were incubated with 0 – 200 nM gemcitabine for 6 h, then the drug was removed and cells incubated for up to 72 h (left). One set of cells (right) were also incubated with 1 μ M MK-8776 from 18-24 h.




Figure S1

Figure S2. Impact of gemcitabine and MK-8776 on cell cycle perturbation of MiaPaCa-2 cells. Cells were incubated with 0 – 200 nM gemcitabine for 6 h, then the drug was removed and cells incubated for up to 72 h (left). One set of cells (right) were also incubated with 1 μ M MK-8776 from 18-24 h.




Figure S2

Figure S3. Impact of gemcitabine on cell cycle perturbation in AsPC-1 (top) and MiaPaCa-2 (bottom) tumor xenografts. Tumors from untreated mice, or mice administered 150 mg/m² gemcitabine were harvested at 18 h. Serial sections from the tumors were stained for Ki67 and geminin. Representative immunohistochemistry is shown. Quantification is presented in Figure 5.

